When: 11.04. - 12. 04. 2013 (9:00 am – 18:30 pm)
Where: ODYSSEUM Köln, Corintostr. 1, 51103 Köln
Registration is free like every year!
We have a restricted number of free rooms for the night from 11. - 12. April for young investigators. Additional rooms and further accommodations are available for special room rates!
Claudia.Mueller@med.uni-duesseldorf.de for registration and accommodation
Resistance testing is meanwhile „standard of care“ Different projects such as AREVIR, the „Verbundprojekt Monitoring von resistenten HIV mit RESINA und der RKI Serokonverter-Analyse“ contribute to better interpretation systems and analyze the risk of transmission of resistant HIV in Germany. On a European level the results of AREVIR and RESINA are integrated into the EUResist project together with the Karolinska and ARCA data and recently other European partners (www.euresist.org ). Our aim is the prediction of the most likely best working drug combinations. For that reason, geno2pheno-THEO (www.genafor.org) was developed and meanwhile integrated into the EUResist prediction tool which is also freely available via internet. Nevertheless we need to understand the contribution of each resistance associated mutation and we have to agree on strategies for resistance testing and interpretation. These are the aims of HIV-GRADE (www.hiv-grade.de).
New drugs in new classes require equivalent diagnostics. Within HIV-GRADE and geno2pheno such new interpretation tools have been developed. This includes the prediction of the co receptor usage prior to therapy with co receptor blockers like maraviroc and resistance to integrase inhibitors like raltegravir.
For HBV the technical expertise from the HIV-projects could be adapted, so that interpretation systems are already available. Geno2pheno and HIV-GRADE predict resistance, (sub-) genotype and escape mutants. In the near future we will have to deal with resistance to anti-HCV drugs and need appropriate tools for interpretation too.
For HCV-therapy a new era has been entered with the availability of direct antiviral agents (DAAs). The protease inhibitors boceprevir and telaprevir are on the market already and polymerase inhibitors are coming soon. Interpretation systems for the prediction of therapy success are needed and geno2pheno[HCV] as well as HIV-GRADE are meeting this challenge.
Since 2000 the meeting is an exchange platform for clinicians, bioinformaticians and virologists. Participants have the chance to discuss clinical cases with other experts – the fasta file of the relevant case from HIV, HBV, HCV and clinical information is needed, while the interpretation systems can be utilized online at the meeting. The suppliers of the commercial systems will also be present. Furthermore, protocols are available at the meeting and will be visible on the internet after the meeting under www.genafor.org.
The language of the meeting is English.
The Meeting is kindly supported by:
ViiV Healthcare, Abbott, AbbVie, Roche, Boehringer Ingelheim, Janssen-Cilag GmbH, Bristol-Myers Squibb, Gilead, Siemens, MSD Sharp & Dohme, QIAGEN
The meeting is certified from the Ärztekammer Nordrhein.
The Meeting is organised by genafor e.V.
Björn Jensen, Daniel Hoffmann, Thomas Lengauer, Francesca Incardona, Maurizio Zazzi, Jens Verheyen, Mark Oette, Rolf Kaiser and Claudia Müller